Moderna (MRNA) Retained Earnings (2017 - 2026)

Moderna (MRNA) has reported Retained Earnings for 10 consecutive years, with $5.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Retained Earnings fell 38.2% year-over-year to $5.1 billion in Q2 2026; TTM through Jun 2026 was $5.1 billion, a 38.2% decrease from a year earlier, with the FY2025 full-year figure at $7.2 billion, down 28.09% from the prior year.
• Retained Earnings was $5.1 billion for Q2 2026 at Moderna, down from $5.9 billion in the prior quarter.
• Over five years, Retained Earnings peaked at $18.4 billion in Q1 2023 and troughed at $5.1 billion in Q2 2026.
• A 5-year average of $12.0 billion and a median of $11.8 billion in 2024 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings jumped 231.14% in 2022 and slumped 38.2% in 2026, its largest moves.
• Over 5 years, Retained Earnings stood at $18.3 billion in 2022, then declined by 25.73% to $13.6 billion in 2023, then slipped by 26.17% to $10.0 billion in 2024, then dropped by 28.09% to $7.2 billion in 2025, then declined by 29.42% to $5.1 billion in 2026.
• The last three Retained Earnings figures came in at $5.1 billion (Q2 2026), $5.9 billion (Q1 2026), and $7.2 billion (Q4 2025), per Business Quant data.